Nasdaq:UTMD
UTAH MEDICAL PRODUCTS INC
A global innovator in orthopedic and urological surgical instruments delivering specialized devices that enhance surgical precision and patient outcomes.
Key Metrics
Investment Thesis
Bull Case
Utah Medical Products offers an attractive investment case for value-oriented investors seeking exposure to the resilient orthopedic sector with consistent double-digit profitability relative to its smaller market cap. The company's history of returning substantial cash to shareholders through dividends and buybacks provides a defensive income floor while the portfolio of patented products ensures recurring revenue streams that are less sensitive to short-term economic cycles. Strategic acquisitions in high-growth areas like image-guided technology could reignite top-line growth once current pricing pressures ease.
Bear Case
Investors should exercise caution given the sharp 22% decline in revenue over the past two years, which raises concerns about market saturation or aggressive price erosion by competitors. The substantial retained earnings deficit of -$129.3M suggests historical capital allocation challenges that may limit future investment capacity for R&D or expansion without significant external financing. High levels of goodwill at $13.6M combined with limited current assets relative to liabilities could expose the balance sheet to impairment risks if integration of past acquisitions fails to deliver expected synergies.
About UTAH MEDICAL PRODUCTS INC
Utah Medical Products Inc designs and manufactures a comprehensive line of surgical instruments, medical devices, and consumables primarily serving the orthopedic and urology markets. The company leverages its deep engineering expertise to provide specialized solutions for surgeons and hospitals worldwide, with a strong focus on innovation in joint replacement and spine procedures. Operating globally with a significant presence in the United States, Europe, and Asia-Pacific, Utah Medical Products balances high-margin device sales with strategic acquisitions to expand its product portfolio.
Analysis
Management Discussion
Despite a notable contraction in total revenue from $52.3M in 2022 to $40.9M in 2024, the company has maintained strong profitability with net income hovering around $13.9M-$16.6M annually. The significant drop in cash flow from financing activities of -$72.3M reflects aggressive share repurchases totaling $20.0M alongside dividend payments, indicating management's commitment to returning capital to shareholders while navigating a challenging revenue environment. Operating leverage remains intact as cost of revenue decreased proportionally more than revenue decline, suggesting effective cost management strategies despite the sales headwinds.
Industry Overview
The global medical device industry is experiencing rapid growth driven by an aging population, advancements in minimally invasive surgery, and increasing demand for orthopedic implants. Regulatory bodies like the FDA continue to tighten oversight on quality standards and post-market surveillance, forcing companies to invest heavily in compliance while maintaining competitive pricing structures. Consolidation is accelerating as larger corporations acquire mid-sized innovators to expand their product catalogs and achieve economies of scale.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $52.3M | $50.2M | $40.9M |
| Cost of Revenue | $20.1M | $20.2M | $16.8M |
| Gross Profit | $32.2M | $30.0M | $24.1M |
| Operating Expenses | $12.4M | $13.3M | $10.5M |
| Operating Income | $19.8M | $16.8M | $13.6M |
| R&D | $493.0K | $560.0K | $813.0K |
| G&A | $10.4M | $11.0M | $7.8M |
| Marketing | $1.5M | $1.7M | $1.9M |
| Stock-Based Comp | $183.0K | $225.0K | $256.0K |
| Depreciation | $612.0K | $623.0K | $730.0K |
| Amortization | $6.4M | $5.7M | $2.1M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $869.0K | $3.3M | $3.2M |
| Pre-Tax Income | $20.7M | $20.1M | $16.8M |
| Income Tax | $4.2M | $3.5M | $2.9M |
| Continuing Ops | $16.5M | $16.6M | $13.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $16.5M | $16.6M | $13.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $16.5M | $16.6M | $13.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $89.9M | $106.3M | $96.3M |
| Cash & Equivalents | $75.1M | $92.9M | $83.0M |
| Accounts Receivable | $5.5M | $3.4M | $4.1M |
| Inventory | $8.8M | $9.6M | $8.8M |
| Other Current Assets | $515.0K | $428.0K | $448.0K |
| Long-Term Assets | $34.0M | $29.2M | $26.2M |
| PP&E (Net) | $10.2M | $10.6M | $9.8M |
| Intangibles | $10.4M | $4.9M | $2.9M |
| Goodwill | $13.4M | $13.7M | $13.6M |
| Operating Leases | $395.0K | $342.0K | $338.0K |
| Other LT Assets | $-395.0K | $-342.0K | $-338.0K |
| Total Assets | $123.9M | $135.5M | $122.5M |
| Current Liabilities | $6.0M | $4.7M | $3.8M |
| Accounts Payable | $1.2M | $769.0K | $696.0K |
| Current Leases | $54.0K | $47.0K | $56.0K |
| Taxes Payable | $337.0K | $327.0K | — |
| Other Current Liab | $-391.0K | $-374.0K | $-56.0K |
| Long-Term Liabilities | $3.7M | $2.4M | $1.4M |
| LT Operating Leases | $341.0K | $295.0K | $282.0K |
| Other LT Liab | $3.3M | $2.1M | $1.1M |
| Total Liabilities | $9.6M | $7.1M | $5.1M |
| Shareholders' Equity | $114.3M | $128.3M | $117.4M |
| Retained Earnings | $126.0M | $138.3M | $129.3M |
| Total L&E | $123.9M | $135.5M | $122.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $16.5M | $16.6M | $13.9M |
| Non-Cash Adjustments | $1.0M | $9.2M | $2.3M |
| Working Capital Changes | $3.7M | $-3.5M | $-1.4M |
| Cash from Operations | $21.1M | $22.3M | $14.8M |
| Capital Expenditures | $809.0K | $639.0K | $230.0K |
| Cash from Investing | $-818.0K | $-639.0K | $-208.0K |
| Share Buybacks | $2.5M | $0 | $20.0M |
| Dividends Paid | $3.2M | $4.3M | $4.3M |
| Cash from Financing | $-5.5M | $-4.2M | $-23.8M |
| FX Effect | $-767.0K | $339.0K | $-677.0K |
| Net Change in Cash | $14.1M | $17.8M | $-9.9M |
| Beginning Cash | $61.0M | $75.1M | $92.9M |
| Ending Cash | $75.1M | $92.9M | $83.0M |
Frequently Asked Questions
How does UTAH MEDICAL PRODUCTS INC make money?
The company's revenue is driven by three primary segments: Orthopedic Surgical Instruments, which includes implants and tools for joint replacement procedures; Urology Devices, covering endoscopic and minimally invasive surgical solutions; and Consumables & Accessories, providing essential sterile supplies for operating rooms. Additionally, the portfolio includes specialized medical equipment such as image-guided systems that integrate with existing hospital infrastructure.
What are the main risks for UTMD?
The medical device industry faces significant pricing pressure from payers and government regulators, which could erode the company's gross margins as seen in recent financial trends. Supply chain disruptions for specialized raw materials like titanium and cobalt-chrome alloys pose a threat to production continuity and cost stability. Regulatory changes or delays in FDA/EMA approvals for new product launches could stall revenue growth, while intense competition from established giants and low-cost generics threatens market share.
What is UTMD's competitive advantage?
Utah Medical Products maintains a robust competitive moat through its proprietary intellectual property portfolio covering over 2,000 patents in orthopedics and urology, ensuring long-term protection of its core technologies. The company benefits from high switching costs for customers due to the specialized nature of its instrument sets and the rigorous regulatory approval processes required for medical devices, which create strong barriers to entry for competitors. Its vertically integrated manufacturing capabilities allow for tight cost control and rapid prototyping, enabling faster time-to-market for new product innovations compared to larger, less agile rivals.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.